751 Gateway South San Francisco, CA Real Estate Partner of Choice for Healthcare Discovery and Delivery February 27, 2026 Disclaimers This Healthpeak Properties, Inc. (the “Company”) presentation is solely for your information, is subject to change…
751 Gateway
South San Francisco, CA
Real Estate Partner of
Choice for Healthcare
Discovery and Delivery
February 27, 2026
Disclaimers
This Healthpeak Properties, Inc. (the “Company”) presentation is solely for your information,
is subject to change and speaks only as of the date hereof. This presentation is not complete
and is only a summary of the more detailed information included elsewhere, including in our
Securities and Exchange Commission (“SEC”) filings. No representation or warranty,
express or implied, is made and you should not place undue reliance on the accuracy,
fairness or completeness of the information presented.
Forward-Looking Statements
Statements contained in this release that are not historical facts are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements include, among other things, statements regarding our and our officers' intent,
belief or expectation as identified by the use of words such as "may," "will," "project,"
"expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential,"
"estimate," "could," "would," "should" and other comparable and derivative terms or the
negatives thereof. Examples of forward-looking statements include, among other things: (i)
statements regarding timing, outcomes and other details relating to the proposed Janus
Living initial public offering ("IPO") or current, pending or contemplated acquisitions,
dispositions, developments, redevelopments, joint venture transactions, leasing activity and
commitments, financing activities, or other transactions discussed in this release; (ii) the
payment of a monthly cash dividend; and (iii) our technology initiatives. The Janus Living
IPO and pending acquisitions, dispositions, joint venture transactions, leasing activity, and
financing activity, including those subject to binding agreements, remain subject to closing
conditions and may not be completed within the anticipated timeframes or at all. Forwardlooking statements reflect our current expectations and views about future events and are
subject to risks and uncertainties that could significantly affect our future financial condition
and results of operations. While forward-looking statements reflect our good faith belief and
assumptions we believe to be reasonable based upon current information, we can give no
assurance that our expectations or forecasts will be attained. Further, we cannot guarantee
the accuracy of any such forward-looking statement contained in this release, and such
forward-looking statements are subject to known and unknown risks and uncertainties that
are difficult to predict. These risks and uncertainties include, but are not limited to: changes
to regulatory, funding, staffing, trade, and other policies and actions by the U.S. political
administration; macroeconomic trends that may increase borrowing, construction, labor and
other operating costs; changes within the life science industry, and significant regulation,
funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting
our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual
obligations to us; the insolvency or bankruptcy of one or more of our major tenants,
operators, or borrowers; our concentration of real estate investments in the healthcare
property sector, which makes us more vulnerable to a downturn in that specific sector than if
we invested across multiple sectors; the illiquidity of real estate investments; our ability to
identify and secure new or replacement tenants and operators; our property development,
redevelopment, and tenant improvement risks, which can render a project less profitable or
unprofitable and delay or prevent its undertaking or completion; the ability of the hospitals on
whose campuses our outpatient medical buildings are located and their affiliated healthcare
systems to remain competitive or financially viable; operational risks associated with our
senior housing properties managed by third parties, including our properties operated
through structures permitted by the Housing and Economic Recovery Act of 2008, which
includes most of the provisions previously proposed in the REIT Investment Diversification
and Empowerment Act of 2007 (commonly referred to as “RIDEA”); the failure of our
tenants, operators, and borrowers to comply with federal, state, and local laws and
regulations, including resident health and safety requirements, as well as licensure,
certification, and inspection requirements; required regulatory approvals to transfer our
senior housing properties; compliance with the Americans with Disabilities Act and fire,
safety, and other regulations; the requirements of, or changes to, governmental
reimbursement programs such as Medicare or Medicaid; economic conditions, natural
disasters, weather, and other conditions that negatively affect geographic areas where we
have concentrated investments; uninsured or underinsured losses, which could result in a
significant loss of capital invested in a property, lower than expected future revenues, and
unanticipated expenses; our use of joint ventures may limit our returns on and our flexibility
with jointly owned investments; our use of rent escalators or contingent rent provisions in our
leases; competition for suitable healthcare properties to grow our investment portfolio; our
ability to exercise rights on collateral securing our real estate-related loans; any requirement
that we recognize reserves, allowances, credit losses, or impairment charges; investment of
substantial resources and time in transactions that are not consummated; our ability to
successfully integrate or operate acquisitions and/or internalize property management; the
potential impact of unfavorable resolution of litigation or disputes and resulting rising liability
and insurance costs; environmental compliance costs and liabilities associated with our real
estate investments; environmental, social and governance and sustainability commitments
and changing requirements, as well as stakeholder expectations; epidemics, pandemics, or
other infectious diseases, and health and safety measures intended to reduce their spread;
our past participation in the Coronavirus Aid, Relief, and Economic Security Act Provider
Relief Fund and other Covid-related stimulus and relief programs; laws or regulations
prohibiting eviction of our tenants; human capital risks, including the loss or limited
availability of our key personnel; our reliance on information technology and any material
failure, inadequacy, interruption, or security failure of that technology; the use of, or inability
to use, artificial intelligence by us, our tenants, our vendors, and our investors; volatility,
disruption, or uncertainty in the financial markets; increased interest rates and borrowing
costs, which could impact our ability to refinance existing debt, sell properties, and conduct
investment activities; cash available for distribution to stockholders and our ability to make
dividend distributions at expected levels; the availability of external capital on acceptable
terms or at all; an increase in our level of indebtedness; covenants in our debt instruments,
which may limit our operational flexibility, and breaches of these covenants; volatility in the
market price and trading volume of our common stock; adverse changes in our credit
ratings; the pending IPO of Janus Living may not be completed on the currently
contemplated timeline or terms, or at all, and may not achieve the intended benefits; our
economic exposure to shifts in the price of Janus Living common stock and our ability to
control the assets and activities of Janus Living; potential conflicts of interest in our
relationship with Janus Living; our ability to maintain our qualification as a real estate
investment trust (“REIT”); our taxable REIT subsidiaries being subject to corporate level tax;
tax imposed on any net income from “prohibited transactions”; changes to U.S. federal
income tax laws, and potential deferred and contingent tax liabilities from corporate
acquisitions; calculating non-REIT tax earnings and profits distributions; tax protection
agreements that may limit our ability to dispose of certain properties and may require us to
maintain certain debt levels; ownership limits in our charter that restrict ownership in our
stock, and provisions of Maryland law and our charter that could prevent a transaction that
may otherwise be in the interest of our stockholders; conflicts of interest between the
interests of our stockholders and the interests of holders of Healthpeak OP, LLC
(“Healthpeak OP”) common units; provisions in the operating agreement of Healthpeak OP
and other agreements that may delay or prevent unsolicited acquisitions and other
transactions; our status as a holding company of Healthpeak OP; and other risks and
uncertainties described from time to time in our Securities and Exchange Commission filings.
Moreover, other risks and uncertainties of which we are not currently aware may also affect
our forward-looking statements, and may cause actual results and the timing of events to
differ materially from those anticipated. The forward-looking statements made in this
communication are made only as of the date hereof or as of the dates indicated in the
forward-looking statements, even if they are subsequently made available by us on our
website or otherwise. Except as required by law, we do not undertake any obligation to
update or supplement any forward-looking statements to reflect actual results, new
information, future events, changes in its expectations or other circumstances that exist after
the date as of which the forward-looking statements were made.
Market and Industry Data
This presentation also includes market and industry data that the Company has obtained
from market research, publicly available information and industry publications. The accuracy
and completeness of such information are not guaranteed. Such data is often based on
industry surveys and preparers’ experience in the industry. Similarly, although Healthpeak
believes that the surveys and market research that others have performed are reliable, such
surveys and market research are subject to assumptions, estimates and other uncertainties
and Healthpeak has not independently verified this information.
Non-GAAP Financial Measures
This presentation contains certain supplemental non-GAAP financial measures. While the
Company believes that non-GAAP financial measures are helpful in evaluating its operating
performance, the use of non-GAAP financial measures in this presentation should not be
considered in isolation from, or as an alternative for, a measure of financial or operating
performance as defined by GAAP. We caution you that there are inherent limitations
associated with the use of each of these supplemental non-GAAP financial measures as an
analytical tool. Additionally, the Company’s computation of non-GAAP financial measures
may not be comparable to those reported by other REITs. You can find reconciliations of the
non-GAAP financial measures to the most directly comparable GAAP financial measures in
the fourth quarter 2025 Discussion and Reconciliation of Non-GAAP Financial Measures
available on our website at http://ir.healthpeak.com/quarterly-results. This document is
hereafter referred to as the “4Q2025 Non-GAAP” in these materials. In addition, the
Appendix to this presentation entitled "Reconciliation of Certain Non-GAAP Financial
Measures" provides updated reconciliations for certain forward-looking non-GAAP financial
measures to their respective most directly comparable GAAP financial measure. Definitions
and a discussion of non-GAAP financial measures presented herein are included in the
4Q25 Non-GAAP.
Other
In connection with the planned initial public offering of Janus Living, Inc., the Company
began evaluating the senior housing business as a single segment, inclusive of the 15 life
plan communities and the 19 senior housing properties during the fourth quarter of 2025. For
purposes of comparing results to original guidance, the 19 senior housing properties
continue to be included in Other throughout this presentation as well as the 4Q25 Non-GAAP
and the Company’s Supplemental Report, but are reported within the Senior Housing
segment on the Company’s Form 10-K and in future presentations and reports.
Investor Presentation – February 27, 2026
2
Recent
Updates
Strategic Initiatives and Commentary
Janus Living
▪ Announced the formation and
planned initial public offering
("IPO") of Janus Living in January
2026
▪ The IPO is intended to enable
Healthpeak to unlock value
immediately and leverage our
industry expertise and relationships
▪ Filed a confidential S-11 with the
SEC on December 19, 2025
▪ Filed a public S-11 on February 27,
2026
Capital Recycling
Technology Initiatives
Lab Fundamentals
▪ Capitalizing on strong private
market demand for outpatient
medical real estate
▪ Focused on automation, superior
and faster decision-making, and
better servicing our clients
▪ Improvement in biopharma M&A
and capital markets activity started
in Fall 2025 and has continued into
2026
▪ Recycling capital into higher growth
opportunities, including senior
housing, pre-leased outpatient
medical developments, and highly
strategic life science campuses
▪ Omkar Joshi joined as Head of
Enterprise Innovation after nearly a
decade at Palantir
▪ Underway on $1B of asset sales,
recapitalizations, and loan
repayments, including $212M
under letter of intent (“LOI”)
Source: CBRE 4Q25 U.S. Life Sciences report.
□ Omkar will lead Healthpeak’s
continued rollout of its agentic
operating system to improve
performance across the back
office and tenant experience
▪ View our Chief Investment Officer
Adam Mabry’s Palantir Paragon
2025 presentation here
▪ Life science real estate
fundamentals are at or near an
inflection point, though a full
recovery will take time
□ New deliveries are approaching
zero
□ Certain life science buildings are
pivoting to alternative uses which
improves the supply overhang
▪ Across the life science sector, the
Bay Area led all markets in leasing
in 2025 and has the highest active
tenant demand(1)
Investor Presentation – February 27, 2026
4
Capital Allocation: Gateway Acquisition
Gateway Blvd Acquisition
Transaction Highlights
Gateway Crossing
1.4M SF | 29 acres
270K SF | 14 acres
▪
▪
Acquired a 1.4M SF campus on 29 acres in South San
Francisco for $600M in late December and early January
Expected low-6% going-in yield with meaningful upside
potential through lease-up of the remaining ~500K SF of
vacancy
▪
The campus consists of 7 buildings, including a 15K SF
amenity space with excellent visibility and accessibility
▪
Combined with our existing Gateway Crossing campus, we
now own 43 contiguous acres which can accommodate
significant additional density over time
▪
Healthpeak’s footprint in the submarket totals ~6.5M SF across
210 acres and solidifies our leadership position in the world’s
most dynamic biotechnology submarket
▪
Across the life science sector, the Bay Area ranked #1 in
leasing volume in 2025 and has the highest active demand(1)
1)
Source: CBRE 4Q25 U.S. Life Sciences report.
Point Grand and Vantage
1.5M SF | 59 acres
Sierra Point
1.2M SF | 46 acres
Edgewater
170K SF | 8 acres
Cove and Portside
2.0M SF | 53 acres
Photo
681 Gateway
751 Gateway
Investor Presentation – February 27, 2026
5
Capital Allocation: Senior Housing Acquisitions
$675M of proprietary investment opportunities sourced in 4Q25 and expected to close in 1Q26
Project
Atlanta MSA
Status
Product Type
Top 25 MSA
80+ Population
Growth %(2)
of Units
of Buildings
Under PSA
Entry Fee and
Rental
✓
42%
354
2
Total
4,063
Units
24
Buildings
Orlando MSA
Under PSA
Rental
✓
42%
354
3
~$675M
Purchase Price
~$297K
Joint Venture Buyout
(46.5% Interest)
Closed Jan-26
Rental
✓
Price / Unit
(1)
39%(3)
3,355
19
8.0% to 9.0%
Targeted Stabilized Cash NOI Yield(4)
92% of the Joint Venture Buyout portfolio (“JV”) is located within Top 25 MSAs.
Population growth from 2024 to 2029. Demographic data from PopStats.
Average growth across markets.
As part of our acquisition underwriting process, we calculate the estimated stabilized Cash NOI yield we expect to derive for each investment opportunity and establish a targeted stabilized
Cash NOI yield range. This range is calculated by dividing the Cash NOI that we aim to derive from the investment opportunity for the twelve months immediately following the anticipated
stabilization date (based on preliminary information provided to us by the sellers and certain assumptions applied by us, including assumptions related to stabilized occupancy (which may
vary between investment opportunities), entrance fees and rental rates and expenses over such period), by the total aggregate purchase price plus anticipated capital expenditures. The
actual stabilized Cash NOI yields from the investment opportunities in our pipeline may not be consistent with the targeted stabilized Cash NOI yield range.
Investor Presentation – February 27, 2026
6
Capital Allocation: Dispositions, Recaps, and Loan Proceeds
$511M in asset sales and loan repayments across 18 transactions closed in 2025; 2026 Guidance includes $1B of proceeds from a
combination of dispositions, recapitalizations, and/or loan repayments
Dispositions
Recapitalizations
Loan Proceeds
■ Active discussions on several transactions
□ Strategic sales to health systems / users
□ Less-core markets / relationships
■ $212M OM recapitalization under LOI
□ 80/20 JV + management fees
□ Long-term leases with lower escalators
■ Blended pricing in the 6-7% cap rate range
■ ~$420M of seller-financing loans have initial
and/or final maturities in 2026
□ Blended ~6% cash | ~7.7% GAAP interest
rates
■ Active JV discussions with blue-chip LPs
□ Core assets; Healthpeak to retain property
management and tenant relationships
■ Blended pricing in the low-6% cap rate range
Galen Auroa
Aurora, CO
Investor Presentation – February 27, 2026
7
Platform Overview
About Healthpeak
Healthpeak is a leading owner, operator, and developer of real estate for healthcare discovery and delivery. Our real estate is uniquely
positioned to benefit from the aging population and universal desire for better health with a high-quality outpatient medical portfolio
affiliated with leading health systems, purpose-built lab campuses, and a high-barrier-to-entry senior housing portfolio with over 10,400
units.
689 Properties
$25B
7%
Baa1 / BBB+
S&P 500
50M SF & 10,422 units
Total Portfolio Investment
Dividend Yield
Credit Ratings
Company
Baylor Scott & White Charles A. Sammons Cancer Center
Dallas, TX – Outpatient Medical Portfolio
Vantage
South San Francisco, CA – Lab Portfolio
Cypress Village
Jacksonville, FL – Senior Housing Portfolio
Investor Presentation – February 27, 2026
Note: Total square footage and property count as of 12/31/25. Total Portfolio Investment as of 12/31/25. Dividend yield based on Healthpeak’s $1.22 annualized dividend and a share price of $17.51
as of 2/26/26. Future dividends are at the discretion of Healthpeak’s Board of Directors. Baa1 credit rating from Moody’s, BBB+ credit rating from S&P Global.
9
Platform with Scale & Deep Relationships to Drive Performance
Institutional platform built to deliver excellence in execution across the portfolio with deep tenant relationships to drive proprietary
opportunities
Outpatient Medical
Lab
Senior Housing
37M SF Portfolio
$807M of Adjusted NOI(1)
13M SF Portfolio
$567M of Adjusted NOI(1)
10,422 units | $197M of Adjusted NOI(2) and $54M
of non-refundable entrance fee sales in excess of
the related GAAP amortization
■ Top 15 markets represent ~65% of total SF providing
local scale and efficiency
■ Portfolio located exclusively in the Bay Area, Boston,
and San Diego
■ Proven asset management capabilities that drive
measurable growth
■ Scaled relationships with leading health systems
■ Mix of price points and suite sizes tailored to meet the
needs of a wide range of biopharma and R&D clients
■ Our team has decades of operational experience,
investment track record, and deep industry relationships
■ Our team is deeply connected in the biotech ecosystem
■ High-quality portfolio located in desirable retirement
markets
■ ~1.3M SF of new development since 2020 with
additional projects in the pipeline
Medical City Dallas
Dallas, TX
Nexus on Grand
South San Francisco, CA
Freedom Pointe at the Villages
The Villages, FL
FY 2025 Portfolio Adjusted NOI, which is Portfolio Cash Real Estate Revenues less Portfolio Cash Operating Expenses. Adjusted NOI excludes all other financial statement amounts
included in net income (loss). Adjusted NOI eliminates the effects of operator transition costs and actuarial reserves for insurance claims that have been incurred but not reported. Refer to
the 4Q25 Non-GAAP.
FY 2025 Adjusted NOI pro forma as though the JV buyout occurred on January 1, 2025.
Investor Presentation – February 27, 2026
10
National Scale with Local Competitive Advantage
Top 20 Markets
Rank
Seattle 2%
Boston 9%
Minneapolis 2%
San Francisco 23%
New York 1%
Salt Lake City 1%
Philadelphia 3%
Indianapolis 1%
Washington DC 2%
Denver 2%
Louisville 3%
San Diego 5%
Phoenix 2%
Nashville 3%
Atlanta 2%
Dallas 8%
Jacksonville 2%
Houston 4%
Orlando 2%
Sized in proportion to % of
Portfolio Adjusted NOI
Tampa 4%
Presence in state
Market
% of Combined NOI(1)
1
San Francisco, CA
23%
2
Boston, MA
9%
3
Dallas, TX
8%
4
San Diego, CA
5%
5
Houston, TX
4%
6
Tampa, FL
4%
7
Philadelphia, PA
3%
8
Louisville, KY
3%
9
Nashville, TN
3%
10
Denver, CO
2%
11
Seattle, WA
2%
12
Phoenix, AZ
2%
13
Atlanta, GA
2%
14
Jacksonville, FL
2%
15
Minneapolis, MN
2%
16
Washington DC
2%
17
Orlando, FL
2%
18
New York, NY
1%
19
Salt Lake City, UT
1%
20
Indianapolis, IN
1%
Remaining
20%
Investor Presentation – February 27, 2026
1)
Represents Portfolio Adjusted NOI as of 4Q25.
11
Diversified Revenue Sources
Unmatched roster of the world’s leading health systems and biopharma companies with only two tenants representing more than 1% of
total ABR
Portfolio Diversification(1)
Top 20 Outpatient and Lab Tenants
Senior Housing
15%
Health Systems
12%
$1.7B
Combined
Annualized
Base Rent(2)
34%
Physician Group
Practices
9%
5%
6%
Small Cap
Biopharma
12%
Large Cap
Biopharma
Mid Cap
Biopharma
7%
Private
Biopharma
Med Device / R&D /
University & Other
Rank
Parent Name
Classification
% of ABR
1
HCA Healthcare
Health System
9%
2
CommonSpirit Health
Health System
3%
3
McKesson Corporation
Health System
1%
4
Roche Holding AG
Large Cap Biopharma
1%
5
Bristol-Myers Squibb
Large Cap Biopharma
1%
6
Northside Hospital
Health System
1%
7
Revolution Medicines
Large Cap Biopharma
1%
8
Alphabet
Large Cap Biopharma
1%
9
University of Louisville
Health System
1%
10
Novo Nordisk
Large Cap Biopharma
1%
11
Ascension Health
Health System
1%
12
Johnson & Johnson
Large Cap Biopharma
1%
13
Arcus Biosciences
Mid Cap Biopharma
1%
14
Astellas Pharma
Large Cap Biopharma
1%
15
HonorHealth
Health System
1%
16
Norton Healthcare
Health System
1%
17
Community Health Systems
Health System
1%
18
Pfizer
Large Cap Biopharma
1%
19
Memorial Hermann
Health System
1%
20
Nkarta
Small Cap Biopharma
1%
Remaining
(1)
(2)
Biopharma market caps as of 12/31/2025. Large Cap Biopharma market cap >$10B; Mid Cap between $10B and $500M; and Small Cap <$500M.
Represents the estimated pro forma quarter Annualized Base Rent (“ABR”) as of 12/31/2025, which reflects the fourth quarter annualized Adjusted NOI, plus fourth quarter annualized nonrefundable entrance fee sales in excess of the related GAAP amortization.
69%
Investor Presentation – February 27, 2026
12
Why Healthpeak
Structural Demand Drivers
Portfolio benefits from an aging population, continued scientific discovery, and the trend toward lower-cost
outpatient care delivery
Portfolio Quality
High-quality Outpatient Medical portfolio leased to leading health systems and specialty physicians, a
critical mass of purpose-built Lab campuses in the three core markets, and over 10,400 Senior Housing
units
Competitive Advantage
Decades of operational expertise and relationships drive internal and external growth opportunities
Balance Sheet Discipline
5.2x Net Debt to EBITDAre(1)
Total Return Opportunity
Well-covered dividend currently yielding ~7%, and a stock price trading below consensus NAV creates a
compelling total return opportunity(2)
Net Debt to Adjusted EBITDAre as of 12/31/25. Refer to 4Q25 Non-GAAP.
Dividend yield based on Healthpeak’s $1.22 annualized dividend and a share price of $17.51 as of 2/26/26.
Investor Presentation – February 27, 2026
13
Outpatient Medical
Overview
Unmatched Outpatient Medical Portfolio and Platform
Best-in-class portfolio and sector-leading tenant relationships differentiates Healthpeak from competitors
Leading Scale &
Portfolio Quality
With Unmatched
Experience &
Health System
Relationships
509
37M
91%
70%
Properties
Square Feet
Occupancy
Leased to Health Systems
96%
5.6 Years
79%
On-Campus or Affiliated
Remaining Lease Term
2025 Retention Rate
Swedish Medical Center
Seattle, WA
UF Health North Medical Building
Jacksonville, FL
+5.0%
2025 Cash Releasing Spreads
with Modest TIs
M Health Clinic and Specialty Center
Minneapolis, MN
Investor Presentation – February 27, 2026
Note: Portfolio data as of 12/31/2025.
15
Two-Year Lookback at the Physicians Realty Trust Merger
Merger synergies and integration outperformed expectations and provided a meaningful improvement to our scale, expanded the depth of
our relationships, and enhanced our platform capabilities with internalized property management operations and expanded internal
leasing
Earnings
Balance Sheet & Capital Recycling Platform & Relationships
■ $70M of realized cost and operational synergies
■ Merger resulted in a bigger and more liquid balance sheet
■ 2024-2025 Outpatient Medical leasing totaled 11M SF
with an average retention rate of 83%, +6% cash
releasing spreads with modest TIs, and +3% annual
escalators on new and renewal leases
■ Combined Outpatient Medical portfolio offers a source of
capital to pursue higher return investments
□ Substantial resurgence in private market interest and
debt availability for outpatient real estate
□ Healthpeak selling and recapitalizing outpatient assets
in the 6-7% cap rate range
■ Healthpeak’s Outpatient Medical same-store growth
accelerated to an average of 3.6% in 2024–2025 vs. an
average of 2.5% in 2019–2023
HCA Swedish
Denver, CO
Calko Medical Center
Brooklyn, NY
■ Combined platform created next-generation of Outpatient
Medical segment leadership
■ 40M SF of Healthpeak Outpatient Medical & Lab are now
internally property managed
■ ~60% of Healthpeak employees now directly support our
clients and real estate
Springwoods Outpatient Medical Facility
Spring, TX
Investor Presentation – February 27, 2026
16
Structural Factors Driving Growth in Outpatient Demand
Advances in technology enable more procedures to be performed outside of the inpatient hospital setting
Baylor Scott & White Charles A. Sammons Cancer Center
Dallas, TX
TOPA Fort Worth
Ft. Worth, TX
8 C1TY Blvd
Nashville, TN
Consumer Preference
Payer Preference
Provider Preference
Convenience & Access
Lower Cost of Care
Higher Margin & Efficiency
▪ Neighborhood-based care with easier parking,
faster scheduling, and shorter wait times
▪ Equal or better health outcomes
▪ Growth in high-deductible health plans driving siteof-care awareness as consumers focus on cost
▪ Lower facility fee vs. inpatient hospital settings
▪ CMS & commercial insurers support for expanding
outpatient procedural eligibility and migrating care
to lower-cost settings
▪ Strong alignment with value-based reimbursement
models
▪ Lower operating costs in outpatient settings while
freeing acute care bed capacity for higherrevenue, complex procedures
▪ Greater scheduling efficiency and throughput
▪ Enhanced physician alignment and referral
capture
Investor Presentation – February 27, 2026
17
Improved Outpatient Real Estate Fundamentals Across All Dimensions
Fundamental backdrop has improved over the past six years and is generating strong NOI growth; renewed investor
demand attracted to consistent, low volatility cash flow growth through market and business cycles
2019
2025
16%
18%
~$375 PSF
~$575 PSF
1.9%
1.2%
Higher Industry Absorption
+13M SF
+15M SF
Higher Industry Occupancy
92%
93%
Higher Annual Rent Bumps(1)
~2.5%
~3%
~50%
~70%
Aging Demographic
percent of US population over 65
Higher Construction Costs
Declining Starts
new starts as % of inventory
Stronger Credit(2)
% leased by health systems
Note: Demographic data from American Community Survey. OM construction cost per square foot, starts, absorption and occupancy from Rivista Top 100 markets.
1)
Refers to Healthpeak’s OM portfolio and represents approximate annual contractual lease escalators achieved for new and renewal leases.
2)
Refers to Healthpeak’s OM portfolio and represents percentage of portfolio leased by health systems.
Improved vs 2019?
Investor Presentation – February 27, 2026
18
Lab Overview
Amenitized Lab Campuses in the Three Leading Markets
Well-located portfolio of amenity-rich spaces for R&D and collaboration
13M
146
3
~85%
Square Feet
Properties
Core Markets
ABR from campuses 400K+ SF
Bay Area
Boston
San Diego
Preeminent lab real estate owner in South
San Francisco, the birthplace of biotech,
bolstered by integration with AI talent
Concentrated in Cambridge and Lexington
with a land bank for future growth
Strategically positioned in Torrey Pines and
West Sorrento Mesa
Nexus on Grand | South San Francisco, CA
Cambridge Discovery Park | Cambridge, MA
The Boardwalk | Torrey Pines, CA
Investor Presentation – February 27, 2026
20
Platform and Portfolio Built for Performance
Healthpeak wisely pulled back on development in 2021 to reduce exposure to sector downturn; now while others are retrenching, we’re
strengthening our portfolio and platform
Tenant Priority Checklist
Healthpeak Competitive Advantage
PrimeLocations
Locations
Prime
Exclusively located in leading submarkets in Bay Area, Boston, and San
Diego
Brand
BrandName
Nameand
andReputation
Reputation
Established industry leader for two decades partnering with clients across
biopharma
High-Quality
High-QualityPortfolio
Portfolio
Purpose-built product at a range of price points and suite sizes to cater to
diverse tenant requirements; ~85% of ABR from campuses 400K+ SF
Scale
Scaleand
andExpertise
Expertise
13M SF portfolio with a strategic land bank to fulfill tenant growth needs
Established
EstablishedIndustry
IndustryRelationships
Relationships
230 tenant relationships overseen by best-in-class local operating
professionals
Capitalization
Capitalizationand
andStability
Stability
Long-term owner with an unencumbered portfolio and investment grade
balance sheet, providing credibility and stability to tenants
Investor Presentation – February 27, 2026
21
Biotech Capital Markets and M&A Accelerating
Positive clinical data, lower interest rates, and less regulatory noise have improved sentiment for the biotech sector and are supporting
the recent improvement in capital raising and M&A activity
Public Biotech Capital Raising Accelerated Post Labor Day 2025
Includes public market follow-on equity issuance, PIPEs, registered direct offerings, and IPOs
$42B
$37B
$26B
$26B
Billion Dollar M&A Activity Has Returned
Announcement
Target
Buyer
Price ($B)
26-Feb
Orna Therapeutics
Lilly
$2
26-Jan
Penumbra
Boston Scientific
$15
26-Jan
Ventyx Biosciences
Lilly
$1
26-Jan
RAPT Therapeutics
GSK
$2
25-Dec
Amicus Therapeutics
BioMarin
$5
25-Dec
Dynavax
Sanofi
$2
25-Nov
Cidara Therapeutics
Merck
$9
Leading to a Strong Recovery for the Biotech Index
$28B PostLabor Day
2022
2023
2024
2025
Biotech equity capital markets data from Wells Fargo. XBI index value as of 2/19/26.
Highest levels since 2021
and +82% off 2025 lows
07/2023
01/2024
07/2024
01/2025
07/2025
01/2026
Investor Presentation – February 27, 2026
22
Senior Housing
Overview
Senior Housing Portfolio Summary
34
10,422
Communities
10
Units
States
100%
$197M
$54M
RIDEA
2025 Adjusted NOI(1)
2025 non-refundable entrance fee sales
in excess of the GAAP related amortization
Unit Mix By Product Type(2)
Attractive Market Concentration(2)
Independent
Living
Tampa, FL
Remaining
12 Markets
20%
69%
19%
9%
Houston, TX
9%
Top 4 Markets
43%
15%
Assisted
Living
89%
5%
11%
Memory
Care
Philadelphia, PA
Orlando, FL
SNF(3)
Represents resident fees and services less property level operating expenses. Adjusted NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI
eliminates the effects of operator transition costs and actuarial reserves for insurance claims that have been incurred but not reported. Adjusted NOI presented above is pro forma as though
the JV buyout occurred on January 1, 2025.
Investor Presentation – February 27, 2026
Percentages based on total units as of 12/31/25.
Skilled nursing units are a component of the continuum offered within certain of the life plan communities; Healthpeak does not own any standalone skilled nursing communities.
24
Senior Housing Portfolio Summary
Properties located in high-growth markets with affluent senior populations; ~70% in Florida and Texas
Geographic Overview
Sized in proportion to Adjusted NOI
Senior housing presence in state
Local Market Scale
MSA
Unit
Count
Tampa, FL
2,049
20%
37%
$407,650
Houston, TX
2,027
19%
39%
$327,321
Philadelphia, PA
965
9%
23%
$421,223
Orlando, FL
923
9%
42%
$434,159
Punta Gorda, FL
634
6%
45%
$364,420
Sarasota, FL
632
6%
40%
$485,579
Denver, CO
592
6%
43%
$652,414
Washington, DC
574
6%
29%
$656,167
Jacksonville, FL
542
5%
43%
$399,396
Grand Rapids, MI
407
4%
26%
$337,797
Chicago, IL
258
2%
26%
$383,382
Birmingham, AL
203
2%
24%
$280,084
Dallas, TX
202
2%
36%
$396,485
Memphis, TN
182
2%
27%
$268,356
Austin, TX
136
1%
46%
$477,885
96
1%
42%
$850,933
36%
$421,426
27%
$380,000
Boulder, CO
Weighted Average
National Average
Population growth from 2024 to 2029. Demographic and median local home sale price from PopStats.
Weighted average based on units.
(2)
% of Total 80+ Population
Median Local
(1)
Units
Growth
Home Sale Price(1)
Investor Presentation – February 27, 2026
25
Life Plan Sector Performance Compared to Rental Senior Housing
High barriers to entry for life plan communities result in limited new supply while the product attracts healthy and active residents with a
10-year average length of stay, providing a consistent, durable growth profile through economic cycles
Entry Fee Life Plan (IAM+SNF)(1)
Occupancy
Asking Rent Growth YoY
92.7%
4Q25
92.4%
93.0%
92.2%
90.7%
90.0%
89.1%
5.1%
4Q25
4.8%
4.5%
3.8%
4Q25
5.1%
3.4%
89.4%
88.7%
Rental Senior Housing
88.5%
87.4%
87.0%
84.9%
3.1%
2.3%
2.5%
4Q25
81.6%
2.5%
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
'09
'10
'11
'12
2.2%
2.2%
1.7%
'13
'14
'15
1.2%
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Entrance Fee(2) ($K)
Inventory Growth YoY
$550
4.3%
4Q25
$485
3.6% CAGR
3.3%
3.3%
$450
2.6%
3.2%
1.3%
1.3%
4Q25
0.6%
0.9%
0.8%
0.4%
'09
'10
'11
'12
'13
'14
'15
0.8%
'16
'17
'18
0.0%
'19
'20
'21
'22
'23
'24
0.4%
4Q25
'25
$350
4Q08
$266
$250
'08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 '19 '20 '21 '22 '23 '24 '25
Source: NIC data as of 02/17/26.
Note: Labeled figures represent 1Q of each year, with the exception of 4Q25.
1)
IAM represents independent living (IL), assisted living (AL), and memory care (MC). SNF stands for skilled nursing facility.
2)
NIC99 average trailing twelve months gross entrance fee. Includes both refundable and non-refundable. NIC calculates the unit-weighted average of each property market EF with the highest refundable %.
Investor Presentation – February 27, 2026
26
Life Plan Campus Case Study
An elevated senior living experience featuring expansive grounds, multiple dining options, wellness and fitness amenities, art &
woodworking studios, entertainment spaces, and numerous outdoor amenities
2
6
1
4
3
5
Freedom Village at Brandywine | 436 Units
1
Private Putting
Green
2
Indoor Heated
Pool & Spa
3
Resident
Garden
4
Bocce Ball &
Gazebo
5
Greenhouse
6
Fine Dining
Café
Theater
Fitness Center
Wellness Center
Game Room
Woodshop
Library
Coatesville, PA | Chester County, PA
Investor Presentation – February 27, 2026
27
Appendix:
Reconciliation of Certain Non-GAAP Financial Measures
Segment Portfolio NOI and Adjusted NOI
For the year ended December 31, 2025
Outpatient
Medical
Net income (loss)
$
Interest income and other
Lab
286,659
$
Other
Non-reportable (1)
Life Plan
131,508
$
21,554 $
Corporate
Non-segment
61,557 $
Total
(400,251) $
101,027
(61,780)
(56,165)
(5,615)
Interest expense
14,077
3,798
287,303
305,178
Depreciation and amortization
621,144
311,364
126,357
1,058,865
General and administrative
Transaction and merger-related costs
Impairments and loan loss reserves (recoveries), net
(Gain) loss on sales of real estate, net
Other (income) expense, net
Income tax (benefit) expense
90,416
90,416
935
1,070
868
22,647
25,520
(893)
(893)
(70,784)
1,296
(69,488)
(2,137)
(197)
4,426
1,212
(3,783)
(479)
9,283
9,283
10,733
171,126
(7,875)
173,984
Healthpeak's share of unconsolidated joint venture NOI
17,994
17,024
23,068
58,086
Noncontrolling interests' share of consolidated joint venture NOI
(27,817)
(38)
(27,855)
Equity (income) loss from unconsolidated joint ventures
Adjustments to NOI(2)
Portfolio Adjusted NOI
(44,043)
$
Pro forma adjustment as though the buyout of the joint venture occurred on January 1, 2025 (3)
Pro forma Portfolio Adjusted NOI
806,761
(64,490)
$
$
806,761
567,367
(2,492)
$
$
567,367
153,643
$
$
153,643
$
29
23,097 $
20,075
43,172
$
(110,996)
$
1,550,868
20,075
$
1,570,943
Portfolio Adjusted NOI for the Other Non-reportable segment relates to Healthpeak's 53.5% share of a 19-community senior housing portfolio.
Adjustments to NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of
deferred community fees expense.
In January 2026, Healthpeak acquired the remaining 46.5% interest in a 19-community senior housing portfolio from its joint venture partner bringing Healthpeak’s ownership of the portfolio to 100%.
Investor Presentation – February 27, 2026
29